|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| New oral contraceptives improve patient compliance. News release. |
| International Working Group on Enhancing Patient Compliance and Oral |
| [Unpublished] [1992]. [2] p. |
| In 1978, the WHO recommended that physicians prescribe for their patients oral contraceptives (OCs) containing the |
| lowest possible effective and acceptable doses of steroid contraceptive preparations so as to minimize any potential |
| risks. Since then, through the synthesis and clinical testing of new, more active, and better tolerated progestational |
| steroids, leading OC manufacturers have developed new hormonal formulations that comply with the WHO |
| recommendations without diminishing the previously high level of OC protection. Recently, Wyeth-Ayerst |
| International Inc., a worldwide leader in female health care, introduced MINULET (75 mcg gestodene and 30 mcg |
| ethinyl estradiol), the next generation of low dose hormonal oral contraception. Gestodene is a 3rd generation |
| progestogen that is very similar to the female hormone progesterone. Gestodene inhibits ovulation effectively. |
| However, physicians know that no matter how effective new OCs are rated, most women will not continue taking them |
| if the experience nuisance side effects such as breakthrough bleeding, weight gain, acne, or nausea. MINULET |
| offers excellent cycle control with minimal side effects for improved patient compliance. The use of minimal side |
| effects for improved patient compliance. The use of OCs may actually provide benefits beyond contraception to a |
| majority of healthy women, especially nonsmokers. These noncontraceptive benefits are significant and include a |
| marked reduction in endometrial and ovarian cancer rates. To further promote patient compliance with OCs, Wyeth- |
| Ayerst International is taking an active role among physicians and OB/GYN specialists to update and educate the |
| public on the major noncontraceptive benefits that are directly related to the use of OCs. The company is also |
| advocating an increased awareness of the various nonmedical or socioeconomic and life style factors that may |
| increase a woman's chances for near perfect compliance. Reflecting the concern over a patient's ability to |
| understand and then stay with the daily dosing regimen of her OCs, for example, the company has developed a |
| unique, simplified, and patient-preferred packaging for MINULET that includes an interactive patient scratchoff start- |
| date reminder. By addressing these patient concerns, this achievement in low-dose OC formulation and packaging |
| will improve patient comfort and compliance with OC prescriptions. Studies indicate that if OC pill taking were |
| improved annually by only 1%, 630,000 fewer women would have unintended pregnancies. Wyeth-Ayerst |
| International's continued commitment to innovative low dose hormonal contraception has also resulted in the newly |
| released triphasic gestodene formulation, TRI-MINULET (gestodene and ethinyl estradiol). TRI-MINULET comes in |
| a 21-day packet and provides a hormonal dose regimen that more closely resembles a woman's natural cycle pattern. |
| Continued international growth of these products is directly attributed to a high level of patient comfort, confidence, |
| and satisfaction, due primarily to a superior cycle control, high efficacy, an improved side-effect profile, and unique |
| patient-preferred packaging. (PubHealth.info Document ID: CONT3T 1584-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "New oral contraceptives improve patient compliance. News |
| release.", is(are) International Working Group on Enhancing Patient Compliance and Oral Contraceptive Efficacy. |
| The source of this article is "[Unpublished] [1992]. [2] p.". This article was published in 1992 in English language(s). |
| (PubHealth.info® Document ID: CONT3T 1584-06. All rights reserved with PubHealth.info) PIN: 11584 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
